Cullinan Therapeutics logo

Cullinan Therapeutics

CGEM | NASDAQ
Chart Builder DCF Calculator
$9.50
-$0.78 (-7.59%)
At close: Nov 16, 2026, 4:00 PM ET
$9.51
+$0.01 (+0.11%)
After-hours: Nov 16, 2026, 7:30 PM ET
-7.59%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
25.4
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #921/1021 (Top 90%)

Key Statistics

Market Data

Market Cap $616.75M
1D Range
9.46 10.28
52W Range
8.45 22.95

Valuation (TTM)

PE -2.91
PB 2.19
EV/EBITDA -1.56

Valuation (NTM)

Forward PE N/A
Forward PEG 0.25
Price Target $35.00
Loading financial charts...

Profile

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD...

Sector Healthcare
Industry Biotechnology
Employees 109
IPO Date Jan 8, 2021
Fiscal Year January - December

Latest News

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

2 months ago · globenewswire.com

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

2 months ago · globenewswire.com

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript

2 months ago · seekingalpha.com

Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

2 months ago · globenewswire.com

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

2 months ago · gurufocus.com

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

2 months ago · globenewswire.com

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset

3 months ago · seekingalpha.com

Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

3 months ago · benzinga.com

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

3 months ago · globenewswire.com

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

4 months ago · globenewswire.com

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

Earnings

Next Earnings
Mar 9, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
3
Consensus
Buy
Price Target
$35.00
Upside
+268.42%
Buy (3)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.